Study links GLP-1 drugs to higher rates of hair and nail issues

A recent analysis involving hundreds of patients reveals that those using GLP-1 medications experience markedly higher instances of hair loss and nail complications than individuals not taking these drugs. The findings, presented this week by European scientists, highlight a significant increase in conditions such as nail detachment among users of semaglutide and tirzepatide.

Research scope and funding details

The investigation was conducted by the SCOP-GLP1 team, comprising researchers from France and Italy. This project received financial support from Pierre Fabre, a major global dermo-cosmetics company that also markets hair loss treatments under brands like Ducray and René Furterer, indicating a commercial interest in the subject matter. Two parallel studies were executed: one examining nail-related changes and the other focusing on hair-related outcomes following GLP-1 use.

Each study compared 575 individuals taking a GLP-1 for type 2 diabetes or obesity against 1,379 control participants with similar conditions who had not initiated GLP-1 therapy. The authors noted that both groups were drawn from representative samples across four countries: France, the United States, Brazil, and Mexico. The average treatment duration for participants was 18.5 months, while researchers monitored weight changes over a three-month period.

Statistical findings on physical side effects

Data indicated that roughly half of the GLP-1 users reported "unusual hair loss," compared to one-third of the control group. Users were also more likely to report scalp irritation. While medical professionals have long recognized that weight loss can trigger temporary hair shedding, the study found no correlation between the likelihood of scalp problems and the amount of weight lost. This suggests that hair issues associated with GLP-1s are not solely caused by weight reduction.

Nail health showed distinct disparities between the two groups. Approximately 66% of GLP-1 users reported general nail problems versus 53% of non-users. The gap widened significantly regarding specific conditions: about 39% of users experienced nail detachment compared to just 9% of controls. Additionally, 46% of those on GLP-1s reported nail discoloration, whereas only 17% of the control group did so.

Expert advice and future study plans

Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris and an author of the study, provided guidance to Gizmodo regarding these findings. He emphasized that patients should not panic or discontinue effective treatments independently due to hair or nail symptoms. Instead, he advised mentioning these issues to their doctors.

The research was presented at the annual conference of the European Academy of Dermatology and Venereology, meaning it has not yet undergone formal peer review. Taïeb cautioned that the cross-sectional nature of the studies, which relied on self-reported symptoms without dermatological examination, describes associations rather than proving causation. Confirmation is needed through prospective studies involving clinical assessments.

The team plans to launch a follow-up study that will proactively monitor individuals starting GLP-1 therapy. This new approach aims to objectively track skin and hair health over time, allowing researchers to better understand the causes of these problems and determine whether they are reversible.